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INTRODUCTION 
 
BACTERIOLOGICAL PROFILE OF Mycobacterium tuberculosis  
Mycobacterium tuberculosis (MTB) is a pathogenic bacterial species in the genus 
Mycobacterium and the causative agent of most cases of tuberculosis (TB) first 
discovered in 1882 by Robert Koch, M. tuberculosis has an unusual, waxy co-antigen, its 
cell surface (primarily mycolic acid), which makes the cells impervious to Gram 
staining
[1]
. Acid-fast detection techniques are used instead. The physiology of 
M.tuberculosis is highly aerobic and requires high levels of oxygen. Primarily a pathogen 
of the mammalian respiratory system, MTB infects the lungs M. tuberculosis requires 
oxygen to grow. It does not retain any bacteriological stain due to high lipid content in its 
wall, and thus is neither Gram-positive nor Gram-negative hence Ziehl-Neelsen staining 
or acid-fast staining is used 
[1]
. M. tuberculosis divides every 15–20 hours, which is 
extremely slow compared to other bacteria. It is a small bacillus that can withstand weak 
disinfectants and can survive in a dry state for weeks. Its unusual cell wall, rich in lipids 
(e.g., mycolic acid), is likely responsible for this resistance and is a key virulence factor. 
 
Tuberculosis, MTB, or TB (short for tubercle bacillus) is a common, and in many cases 
lethal, infectious disease caused by various strains of mycobacteria, usually 
Mycobacterium tuberculosis 
[4]
. Tuberculosis typically attacks the lungs, but can also 
affect other parts of the body. It is spread through the air when people, who haven active 
TB infection, cough, sneeze, or otherwise transmit their saliva through the air. Most 
infections are asymptomatic and latent, but about one in ten latent infections eventually 
progresses to active disease which, if left untreated, kills more than 50% of those so 
infected. Consumption, phthisis, scrofula, Pott's disease, and the White Plague are all 
terms used to refer to tuberculosis throughout history. It is generally accepted that the 
microorganism originated from other, more primitive organisms of the same genus 
Mycobacterium. Human bones from the Neolithic show a presence of the bacteria, 
although the exact magnitude (incidence and prevalence) is not known before the 19th 
century. The first references to tuberculosis in Asian civilization are found in the Vedas 
[5]
. The oldest of them (Rig-Veda, 1500 BC) calls the disease yaksma. The Atharvaveda 
calls it another name: balasa. It is in the Atharvaveda that the first description of scrofula 
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is given. The Sushruta Samhita, written around 600 BC, recommends that the disease be 
treated with breast milk, various meats, alcohol and rest. The Yajurveda advises sufferers 
to move to higher altitudes. Aretaeus was the first person to rigorously describe the 
symptoms of the disease in his text De causis et signis diuturnorum morborum:―Voice 
hoarse; neck slightly bent, tender, not flexible, somewhat extended; fingers slender, but 
joints thick; of the bones alone the figure remains, for the fleshy parts are wasted; the 
nails of the fingers crooked, their pulps are shrivelled and flat...Nose sharp, slender; 
cheeks prominent and red; eyes hollow, brilliant and glittering; swollen, pale or livid in 
countenance; the slender parts of the jaws rest on the teeth as, as if smiling; otherwise of 
cadaverous aspect...‖ 
 
PATHOGENESIS OF TUBERCULOSIS
 
 
In the lungs, M. tuberculosis is taken up by alveolar macrophages, but they are unable to 
digest the bacterium. Its cell wall prevents the fusion of the phagosome with a lysosome. 
Specifically, M. tuberculosis blocks the bridging molecule, early endosomal auto antigen 
1(EEA1); however, this blockade does not prevent fusion of vesicles filled with nutrients. 
Consequently, the bacteria multiply unchecked within the macrophage 
[11]
. The bacteria 
also carried the UreC gene, which prevents acidification of the phagosome. The bacteria 
also evade macrophage-killing by neutralizing reactive nitrogen intermediates. 
 
M. tuberculosis usually enters the alveolar passages of exposed humans in an aerosol 
droplet, where its first contact is thought be with resident macrophages, but it is also 
possible that bacteria can be initially ingested by alveolar epithelial type II Pneumocytes. 
This cell type is found in greater numbers than macrophages in alveoli, and M. 
tuberculosis can infect and grow in these pneumocytes ex vivo. In addition, dendritic 
cells play a very important role in the early stages of infection since they are much better 
antigen presenters than are macrophages and presumably play a key role in activating T 
cells with specific M. tuberculosis antigens 
[7]
. Since dendritic cells are migratory, unlike 
differentiated macrophages, they also may play an important role in dissemination of M. 
tuberculosis. The bacteria are phagocytized in a process that is initiated by bacterial 
contact with macrophage mannose and/or complement receptors. Surfactant protein A, a 
glycoprotein found on alveolar surfaces, can enhance the binding and uptake of M 
tuberculosis by up regulating mannose receptor activity. On the other hand, surfactant 
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protein D, similarly located in alveoli, inhibits phagocytosis of M. tuberculosis by 
blocking mannosyl oligosaccharide residues on the bacterial cell surface, and it is 
proposed that this prevents M.tuberculosis interaction with mannose receptors on the 
macrophage cell surface. The human toll-like receptor 2 (TLR2) also plays a role in M. 
tuberculosis uptake 
[12]
. On entry into a host macrophage, M. tuberculosis resides in an 
endocytic vacuole called the phagosome. If the normal phagosomal maturation cycle 
occurs, i.e., phagosome-lysosome fusion, these bacteria can encounter a hostile 
environment that includes acid pH, reactive oxygen intermediates (ROI), lysosomal 
enzymes, and toxic peptides 
[22]
.  
 
 MICROSCOPY  
Owing to their high lipid content in cell walls, M.tuberculosis cannot be identified by 
Gram‘s staining. Acid-Fast staining or Ziehl-Neelsen staining is employed to identify the 
organisms. M. tuberculosis is characterized by caseating granulomas containing 
Langhans giant cells, which have a "horseshoe" pattern of nuclei. Organisms are 
identified by their red colour on acid-fast staining 
[14]
. 
 
Fig 01 – M.tuberculosis                                 
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TYPES OF TUBERCULOSIS   
Tuberculosis is a contagious disease that affects almost all the important organs of the 
body. Clinically, tuberculosis is broadly categorized into three major categories. 
Primary Tuberculosis: 
When tuberculosis affects a person who had never been exposed to the bacterium earlier, 
the condition is called primary tuberculosis. In this form of tuberculosis, the source of 
bacterium is external 
[17]
. In primary tuberculosis the lymph nodes get affected leading to 
their swelling. Lesions are also formed which are removed during treatment. The 
removal of the lesion does not indicate bacterial removal as the bacteria may have gone 
into a dormant phase and if left untreated, it can cause TB when favourable condition 
comes
 [19]
. 
Secondary Tuberculosis 
It is also known as post-primary tuberculosis. This type of tuberculosis occurs in a person 
who previously had TB. In primary TB, the bacterium goes into an inactive phase while 
in secondary tuberculosis; the bacterium regains its active mode and causes the 
symptoms 
[17]
. Secondary tuberculosis is mostly localized to lungs as oxygen pressure is 
highest there. Secondary tuberculosis is more infectious than primary tuberculosis. 
Secondary TB increases the chance of the infection‘s spread to other organs such as 
kidneys, heart and brain. 
Disseminated Tuberculosis 
Disseminated tuberculosis means that the tuberculosis has infected the entire body 
system. It is a very rare type of disease. Disseminated TB primarily affects the bones of 
spines, hips, joints and knees, the genital tract of women, the urinary tract and even the 
central nervous system 
[23]
. It infects the cerebrospinal fluids, the gastro intestinal tract, 
the adrenal gland, skin of the neck and even the heart. 
 
MEDICINAL CHEMISTRY 
 
Medicinal chemistry is the applied science that is based on the drug design and discovery 
of new chemical entities and their optimization and development existing as useful drug 
molecules for the therapeutic purpose 
[9]
. It is also a multi-disciplinary approach drawing 
on theoretical chemistry, organic chemistry, analytical chemistry, molecular biology, 
pharmacology and bio-chemistry 
[9]
. 
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DRUG DISCOVERY
  
The process of drug discovery involves designing, synthesizing, characterization and 
biological screening of newer chemical entities which would be applicable for 
therapeutic use(s). This process includes the study of existing drug molecules, reports of 
biological screening properties and their QSAR. Discovery is the process of identifying 
the active novel compounds so called Hits that are typically found by evaluating more 
compounds for predicting desired biological properties 
[24]
. Besides a number of 
approaches in identifying the active Hits, the most reliable technique is applicable based 
on physico-chemical properties and biological screening. The other sources where Hits 
exist namely from natural sources, synthetic chemical libraries from combinatorial 
chemistry or from collecting historical compounds are evaluated against the biological 
target 
[31]
. 
 
LEAD OPTIMIZATION 
Lead optimization is a complex, non-linear process. During this stage of drug discovery, 
the chemical structure of a confirmed hit is refined to improve its drug characteristics 
with the goal of producing a preclinical drug candidate. Typically, confirmed hits are 
evaluated in secondary assays, and a set of related compounds, called analogues, are 
synthesized and screened. The testing of analogue series results in quantitative 
information that correlates changes in chemical structure to biological and 
pharmacological data to establish structure-activity relationships (SARs) 
[21]
. Today, lead 
optimization often involves a series of standard assays to evaluate toxicity, including P450 
inhibition and cytotoxicity assays. Toxicity in these relatively simple in vitro assays flags 
hits or leads that could have potential safety concerns. Another characteristic that lead 
optimization often evaluates is formulation 
[25]
. Formulation and delivery are closely 
linked. For example, a drug intended to be delivered via intramuscular injection might 
call for a different formulation than would one intended for oral delivery. Formulation 
problems and solutions feed back into the iterative lead optimization cycle. Molecular 
Devices offers a range of products that are particularly well suited for lead optimization 
studies 
[32]
. 
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DRUG DESIGN   
Methodologies used in drug design have changed over time, exploiting and driving new 
technological advances to solve the varied bottlenecks found along the way. While until 
the 90s, the major issues were lead discovery and chemical synthesis of drug-like 
molecules, the emergence of combinatorial chemistry gene technology, and high-
throughput tests shifted the focus, with poor absorption, distribution, metabolism, and 
excretion (ADME) properties of the new drugs capturing more attention today, the field 
of drug development may seem more fertile than ever before, with vast amounts of 
information from genomic and proteomic studies facilitating the finding of new targets, 
the usage of rational combinatorial chemistry for the production of libraries of 
compounds, the generation of genetically modified animal models for the development 
and testing of new drugs, and the possibility of using ultra-high-throughput test 
techniques for the screening of large libraries 
[3,27]
. However, despite all these advances, 
the revolutionary era of drug design has not arrived yet. A variety of computational 
approaches can be applied at different stages of the drug-design process: in an early 
stage, this focus on reducing the number of possible ligands, while at the end, during 
lead-optimization stages, the emphasis is on decreasing experimental costs and reducing 
times 
[26]
. Although this is simple to articulate, it has been tried many times with only a 
few fruitful examples.  
 
RATIONAL DRUG DESIGN 
 
When the structure of the target protein is known, the drug discovery process usually 
follows a well-established procedure and it is shown schematically in Figure 2. Virtual 
screening techniques are applied early during the docking protocol to reduce the size of 
large compound libraries 
[25]
. Initially, libraries are ‗‗pre-filtered‘‘ using a series of simple 
physicochemical descriptors to eliminate compounds not expected to be suitable drugs. 
Pharmacophore analysis, neural nets, similarity analysis, scaffold analysis, Lipinski‘s rule of 
five and garbage filters are used to sort out molecules according to their ADME properties, 
among others 
[34]
. This procedure, which reduces the size of the library to a group of 
molecules more likely to bind the target receptor, is known as enrichment. It is necessary to 
stress that the selection criteria used during the enrichment steps need to be carefully chosen, 
as application of too stringent filters may lead to early exclusion of potential leads Similarly, 
drug-likeness of potential leads may be less important at the early stages than ease of the 
molecule to experimental validation with in vitro assays and X-ray crystallography 
[34]
. 
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Similar compounds can be further grouped together and arranged in smaller assemblies to 
assist the screening process. The use of several small libraries is not only a more cost-
effective approach, but can usually provide a broader chemical diversity than a single large 
library 
[31]
. Once an optimum library has been produced, molecules are docked to the target 
receptor to reduce further the number of candidates. This initial screening makes use of fast, 
but not very accurate, ranking functions to evaluate the relative stability of the docked 
complexes. The selected candidates, usually a few hundred, are subject to further docking 
experiments using more sophisticated scoring functions 
[32]
.  
Mycolic acids are major components of the cell wall of Mycobacterium tuberculosis. 
Several studies indicate that functional groups in the acyl chain of mycolic acids are 
important for pathogenesis and persistence. The mycolic acid cyclopropane synthases 
(CmaA1) those are responsible for these site-specific modifications of mycolic acids. To 
derive information on the specificity and enzyme mechanism of the family of proteins, the 
crystal structures of CmaA1 were solved to 2-A resolution 
[19]
. The enzymes have a seven-
stranded alpha/beta fold similar to other methyltransferases with the location and 
interactions with the cofactor S-adenosyl-l-methionine conserved. The structures of the 
ternary complexes demonstrate the position of the mycolic acid substrate binding site. Close 
examination of the active site reveals electron density that we believe represents a 
bicarbonate ion. The structures support the hypothesis that these enzymes catalyze methyl 
transfer via a carbocation mechanism in which the bicarbonate ion acts as a general base. In 
addition, comparison of the enzyme structures reveals a possible mechanism for substrate 
specificity. These structures provide a foundation for rational-drug design, which may lead 
to the development of new inhibitors effective against persistent bacteria 
[19]
.     
Figure-2: 3D view of cmaA1 (1L1E) protein 
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DOCKING 
Docking techniques, designed to find the correct conformation of a ligand and its 
receptor, have now been used for decades. The process of binding a small molecule to its 
protein target is not simple; several entropic and enthalpic factors influence the 
interactions between them. The mobility of both ligand and receptor, the effect of the 
protein environment on the charge distribution over the ligand, and their interactions with 
the surrounding water molecules, further complicate the quantitative description of the 
process 
[8]
. The idea behind this technique is to generate a comprehensive set of 
conformations of the receptor complex, and then to rank them according to their stability. 
The most popular docking programs include DOCK, Auto Dock, Flex X, GOLD, and 
GLIDE, among others 
[4, 13, 20, and 25]
. 
 
PROTEIN PREPARATION 
 
It is now accepted that the old idea of the ‗‗key and lock‘‘ interaction of a ligand and its 
protein Receptor is not an accurate description of most biological complexes. The 
ligand–protein interactions resemble more a ‗‗hand and glove‘‘ association, where both 
parts are flexible and adjust to Complement each other—induced fit [40]. They can modify 
their shape and mould their complementarity. So as to increase favourable contacts and 
reduce adverse interactions, maximizing the total binding free Energy. It has been found 
that active-site regions of enzymes appear to present areas of both low and high 
conformational stability 
[9]
. Mobile loops that close over the ligand upon binding are 
included within the flexible parts, while catalytic residues, for example, and are usually 
structurally stable. This dual character of the active-site environment appears important 
for optimum binding 
[9]
.  
 
RECEPTOR CONFORMATION   
The three dimensional (3-D) structures of both ligand and protein are necessary for the 
application of docking techniques. While the manifold of conformational structures of 
small molecules may be relatively easy to predict, the lowest energy conformation 
obtained may not correspond to that of the bound ligand. The structures of proteins 
present a bigger challenge 
[37]
. Although experimental techniques involving x-ray and 
NMR Analysis are now in routine, inherent difficulties in the preparation of samples and 
data collection and interpretation mean we are still far from a complete automated and 
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High-throughput process. Many proteins targeted for drug design do not have an 
experimentally determined structure and, therefore, docking studies cannot be performed 
directly. In some cases, Computational techniques can be used to predict the 3-D 
structure of a protein provided the structure of a closely related protein homolog is 
known 
[41]
. Homology modelling or sequence threading Techniques may be used to 
generate models of protein structure which, although not as good as experimentally 
determined structures, can be used as docking targets.  
 
 
 Figure-3: Schematic representation of the protocol commonly followed during a drug-
design process, when the structure of the protein target is known 
[11]
. 
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THE FIELD OF HETEROCYCLIC CHEMISTRY 
 
Hetero cycles have been contributed their presence in the field of research and development 
in organic chemistry. As a result, millions of heterocyclic compounds found to exist in 
natural source, semi-synthesized and synthesised having special properties with biological 
importance. Recently, analysis of organic compounds as of June 2007 there were 
24,282,284 compounds were registered in chemical abstracts containing cyclic structures 
with heterocyclic systems making up of many compounds 
[28]
. Among various heterocyclic 
compounds, we have chosen isatin, it possess an indole nucleus having both the keto and 
lactam moiety 
. 
ISATIN  
Isatin [1H-indole-2, 3- dione] was first obtained by Erdman and Laurent in 1841 as a 
product from the oxidation of indigo by nitric and chromic acids. In nature, isatin is found in 
plants of the genus isatis 
[39]
. Substituted isatins are found in plants, for example the 
melosatin alkaloids (methoxy, phenyl, and pentyl isatins) obtained from the Caribbean 
tumorigenic plant. 
  
Indole nucleus is found to be very active scaffold in pharmacy field as several natural 
alkaloids having indole in its structures are found to be therapeutically active agents. Isatin 
(Indole-2, 3-Dione) is an endogenous compound identified in humans that possesses indole 
nucleus with wide range of biological activities 
[40]
. Isatin and its synthetic analogues are 
versatile substrates, which can be used for the synthesis of plentiful heterocyclic derivatives. 
This review mainly focused on the updated information on the most active isatin derivatives 
that have been reported to show significant biological actions for instance, Anti-
mycobacterial, Anti-HIV, Anticonvulsant, Anticancer, Antiviral, Antimicrobial, Anti-
inflammatory and Analgesic. From these outcomes, information for future molecular 
modifications leading to compounds with significant pharmacological properties may be 
derived 
[8, 33]
.  Indoline-2, 3-dione (isatin) derivatives are reported to show anti-tubercular 
activities; accordingly isatin is a versatile lead molecule for designing of potential anti-
tubercular agent 
[32]
.  
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Sandmeyer Diphenylurea Isatin Synthesis 
[28] 
Formation of a cyanoformamidine by treatment of a symmetrical diphenylthiourea with 
potassium cyanide in alcohol containing lead carbonate, reduction with ammonium sulfide 
and ring-closure with concentrated sulfuric acid to isatin-2-anil; also formed smoothly by 
ring closure of the cyanoformamidine with aluminum chloride in benzene or carbon 
disulfide: 
 
Sandmeyer Isonitrosoacetanilide Isatin Synthesis 
[30] 
Formation of isonitraso aceto diphenyl amidine by condensation of chloral hydrate, 
hydroxylamine and aniline, cyclization with concentrated sulfuric acid, and quantitative 
hydrolysis to isatin on dilution: 
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M-PHENYLENE DIAMINE 
 
m-Phenylene diamine, also called 1, 3-diaminobenzene, is an organic compound with the 
formula C6H4 (NH2)2. It is an isomer of o-phenylene diamine and p-phenylene diamine. It is 
a colourless solid. m-Phenylene diamine is produced by hydrogenation of 1, 3-
dinitrobenzene 
[20]
. The dinitrobenzene is prepared by di nitration of benzene. m-Phenylene 
diamine is used in the preparation various polymers including aramid fibres, epoxy resins, 
wire enamel coatings and poly urea elastomers 
[29]
. m-phenylene diamine is used as an 
accelerator for adhesive resins, and as a component of dyes for leather and textiles 
[35]
. Basic 
Brown 1 (Bismarck Brown), Basic Orange 2, Direct Black 38, and Developed Black BH In 
hair-dying, m-phenylene diamine is a "coupling agent", used to produce blue colours 
[32]
.  
 
BIOLOGICAL SCREENING 
 
 
Microbial assays or microbiological assays is a type of bioassay and are designed to analyse 
the compounds or substances which have effect on micro-organisms. Microbiological assay 
is defined as the determination or estimation of concentration or potency of an antibiotic by 
means of measuring and comparing the area of zone of inhibition or turbidity produced by 
test substance with that of standard over a suitable microbe under standard conditions 
[10]
. 
So as definition says the hypothesis is that when an antibiotic is administered, there is 
inhibition in the growth of microbe as indicated by decrease in area of zone of microbial 
colony on nutrition media or decrease in turbidity due to decrease in microbial 
concentration. 
 
Uses of microbial assay: 
1. This helps to estimate concentration and potency of antibiotics 
[9]
. This is not always 
possible by other means of estimations. 
2. Help in determination of the best anti-biotic suitable for patient recovery. When microbe 
in patients phlegm or urine is examined by bioassay the better susceptibility of microbe to 
the suitable anti-biotic among those available to treat can be decided for proper treatment of 
infected patient. This determination is possible by immune assays like ELISA test for some 
diseases 
[28]
. 
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Alamar Blue
®
 ASSAY FOR ESTIMATING THE MICROBIAL VIABILITY 
 
 
Alamar Blue
®
 is designed to provide a rapid and sensitive measure of cell proliferation and 
cytotoxicity in various human and animal cell lines, bacteria and fungi. It is simple to use as 
the indicator dye is water soluble, thus eliminating the washing/fixing and extraction steps 
required in other commonly used cell proliferation assays 
[27]
. 
 
The assay incorporates a specially selected oxidation-reduction (REDOX) indicator that 
both fluoresces and undergoes colorimetric change in response to cellular metabolic 
reduction. This offers the user a choice of detection method. 
 
Alamar Blue
®
 reagent contains Resazurin (7-Hydroxy-3H-phenoxazin-3-one 10-oxide) a 
blue dye, which itself is non-fluorescent until it is reduced to the pink colour and highly red 
fluorescent resorufin. It is used mainly as an oxidation-reduction indicator in cell viability 
assays for bacteria and mammalian cells. Usually it is available commercially as the sodium 
salt. 
 
PRINCIPLE: 
 
  Growing cells cause a chemical reduction of alamar Blue
®
. 
  Continued growth maintains a reduced environment (fluorescent, red). 
  Inhibition of growth maintains an oxidized environment (non-fluorescent, blue). 
  Data may be collected using either fluorescence-based or absorbance-based 
instrumentation. 
  Fluorescence is monitored at 530-560 nm excitation wavelength and 590nm emission 
wavelength. 
  Absorbance is monitored at 570 nm and 600 nm. 
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ASSAY PROTOCOL FOR ESTIMATING ANTI-TB ACTIVITY USING alamarBlue® 
DYE 
[27] 
 
1. The anti-mycobacterial activity of compounds were assessed against M. Tuberculosis 
using alamarblue® micro plate assay (MABA). 
2. This methodology is non-toxic, uses a thermally stable reagent and shows good 
Correlation with proportional and BACTEC radiometric method. 
3. Briefly, 200μl of sterile de-ionized water was added to all outer perimeter wells of Sterile 
96 wells plate to minimized evaporation of medium in the test wells during Incubation. 
4. The 96 wells plate received 100 μl of the Middle brook 7H9 broth and serial dilution of 
compounds were made directly on plate. 
5. The final drug concentrations tested were 100 μg/ml to 0.2 μg/ml. 
6. Plates were covered and sealed with paraffin and incubated at 37ºC for five days. 
7. After this time, 25μl of freshly prepared 1:1 mixture of alamar blue® reagent and 10% 
tween 80 was added to the plate and incubated for 24 hrs. 
8. A blue colour in the well was interpreted as no bacterial growth, and pink colour was 
scored as growth.  
9. The MIC was defined as lowest drug concentration which prevented the colour change 
from blue to pink. 
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SURVEY OF LITERATURE 
 
 
The purpose of a literature review is to: 
 
 establish a theoretical framework for a topic / subject area 
 Define key terms, definitions and terminology 
 Identify studies, models, case studies etc. supporting a topic 
 Define / establish an area of study. 
 
Literature survey was conducted to have updates about the advances in genomics related 
to TB, current moieties under research for TB, synthetic pathways, current understanding 
of the pathophysiology of TB and advances in screening methods. 
 
The following literature was surveyed in depth to provide supporting data for drug 
design study  
  
 Jürgen Bajorath (2001) did his work on rational drug discovery revisited: 
Interfacing experimental programs with bio- and chemo-informatics 
 Maria van Dongen et al (2002) worked on “Structure-based screening and 
design in drug discovery” 
 Daniel F. Wyss (2003) reported his work on “Structure-guided applications in 
drug discovery” 
 Alexander Hillisch et al (2004) reported the “Utility of homology models in the 
drug discovery process” 
 I.M. Kapetanovic (2008) published his work on “Computer-aided drug 
discovery and development (CADDD): In silico-chemico-biological approach”. 
 Sanat K. Mandal et al (2009) published their work on rational drug design. 
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The following works throws a light upon the various genomic aspects of 
M.tuberculosis and also various targets intended for drug action 
 
 Ashok Rattan et al (1998) published his work on “Multidrug-Resistant 
Mycobacterium tuberculosis: Molecular Perspectives”. 
 J. Brennan (2003) reported his work on “Structure, function, and biogenesis of 
the cell wall of Mycobacterium tuberculosis”. 
 Puneet Chopra et al (2003) reported new drug targets for Mycobacterium 
tuberculosis 
 James C Sacchettini et al (2003) reported “Mycobacterium tuberculosis: a 
model system for structural genomics”. 
 C. Terwilliger et al (2003) published his work on “The TB structural genomics 
consortium: a resource for Mycobacterium tuberculosis biology”. 
 R. Hernandez Pando et al (2006) published their work on the use of mutant 
mycobacteria as new vaccines to prevent tuberculosis. 
 Vickery L.Arcus et al (2006) observed the potential impact of structural 
genomics on tuberculosis drug discovery 
 Khisimuzi Mdluli and Melvin Spigelman (2006) reported “Novel targets for 
tuberculosis drug discovery” 
 Johan Weigelt et al (2008) published their work correlating “Structural 
genomics and drug discovery: all in the family”. 
 Nagasuma Chandra et al (2008) reported a target identification pipeline for 
Mycobacterium tuberculosis through an interactome, reactome and genome-scale 
structural analysis 
 Yee Siew Choong (2011) reported the “Effects of Enoyl-Acyl Protein Carrier 
Reductase Mutations on Physiochemical Interactions with Isoniazid: Molecular 
Dynamics Simulation”. 
 Anshu Bhardwaj et al (2011) published their work on “Open source drug 
discovery– A new paradigm of collaborative research in tuberculosis drug 
development”. 
 T. Cole et al (1992) worked on “Isolation and characterization of isoniazid 
resistant mutants of Mycobacterium smegmatis and M. aurum” 
LITERATURE REVIEW 
 
 
DEPARTMENT OF PHARMACEUTICAL CHEMISTRY 
 
17 
 Dorothy Yeboah-Manu et al (2012) conducted a study on “Drug Susceptibility 
Pattern of Mycobacterium Tuberculosis Isolates from Ghana; Correlation with 
Clinical Response”.  
 
The review on following works provided basic information about the target 
enzyme, mycolic acid cyclopropane synthase [CmaA1 target (1L1E)] and its 
function 
 
 Chih-chin Huang et al (2002) conducted a study on “Crystal Structures of 
Mycolic Acid Cyclopropane Synthases from Mycobacterium tuberculosis”. 
 Kuni Takayama et al(2005) reported a “Pathway to Synthesis and Processing 
of Mycolic Acids in Mycobacterium tuberculosis” 
 
The review on following works provided ideas for synthesis of the desired chemical 
entities 
 Razieh Sabet, Mehrdad Mohammadpour, Amir Sadeghi, Afshin Fassihi, 
reported “QSAR study of isatin analogues as in vitro anti-cancer agents”, 
European Journal of Medicinal Chemistry 45 (2010) 1113–1118. 
 Razieh Sabet et al., (2010) reported a “QSAR study of isatin analogues as in 
vitro anti-cancer agents”. 
 Isabel Amalia Perillo et al., (2008) reported a “Simple and Efficient 
Microwave Assisted N-Alkylation of Isatin”. 
 Chaluvaraju KC et al., (2011) reported a “Synthesis and Biological Evaluation 
of some Isatin derivatives for Antimicrobial Properties”. 
 Manjusha Verma et al., (2004) reported a Anticonvulsant activity of Schiff 
bases of isatin derivatives. 
 Tarek Aboul-Fadl et al., (2010) studied about the “Anti-Tubercular Activity of 
Isatin Derivatives”. 
 Tarek Aboul-Fadl et al., (2010) studied about the “Schiff bases of indoline-2,3-
dione (isatin) derivatives and nalidixic acid carbohydrazide synthesis”. 
 Lin Hou et al., (2008) reported an “Anti-tumour effect of Isatin on human 
neuroblastoma cell line (SH-SY5Y)”. 
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 E.G. Mesropyan et al., (2005) reported a “Synthesis of Isatin and 5-
Bromoisatin Derivatives”. 
 L.-R. Chen et al., (2010) studied “Bio-organic synthesis and evaluation of isatin 
derivatives as effective SARS coronavirus 3CL protease inhibitors”. 
 Ward C. Sumpter (1943) gave the information about the chemistry of isatin. 
 
 
The review on following works revealed the basics of Alamar blue assay for 
evaluating the anti-mycobacterial action 
 
 Page et al (1993) conducted “A New Fluorometric Assay for Cytotoxicity 
Measurements Invitro”. 
 Geier, Steven (1994) published his work on “Analysis of alamar Blue Overlap: 
Contribution of Oxidized to Reduced”. 
 Lancaster, M.V. and Fields, R.D. (1996) carried out “Antibiotic and Cytotoxic Drug 
Susceptibility Assay’s using Resazurin and Poising Agents”. 
 R Hamid et al (2004) carried out “Comparison of alamar blue and MTT assays 
for high through-put screening” 
 C. N. Paramasivan et al (2004) carried out “Evaluation of micro plate Alamar 
blue assay for drug susceptibility testing of Mycobacterium avium complex 
isolates”. 
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AIM AND OBJECTIVES 
 AIM 
To design, synthesis, characterize and evaluate compounds for their potential anti-
tubercular activity .The ability of compounds to inhibit cell wall synthesis by inhibiting 
Mycolic acid cyclopropane synthase [cmaA1 target (1L1E)] is to be evaluated. 
OBJECTIVES 
 
DESIGN 
In-silico design of Mycolic acid cyclopropane synthase [cmaA1 target (1L1E)] 
inhibitors. 
SYNTHESIS 
 
                Based upon the Docking parameters and synthetic feasibility the following 
compounds will be synthesized. 
 
A.     (3Z)-3-[(3-{[(E)-phenylmethylidene]amino}phenyl)imino]-1,3-dihydro-2H-indol-2-
one. 
B.     (3Z)-3-[(3-{[(E)-(4-methoxyphenyl)methylidene]amino}phenyl)imino]-1,3-dihydro-
2H-indol-2-one. 
C.     (3Z)-3-[(3-{[(E)-(2-hydroxyphenyl)methylidene]amino}phenyl)imino]-1,3-dihydro-
2H-indol-2-one. 
 
CHARACTERIZATION: 
The above synthesised compounds will be identified and characterized by using 
 Melting point, 
 TLC method, 
 Infrared Spectroscopy,  
 Nuclear Magnetic Spectroscopy, 
 Mass spectroscopy. 
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BIOLOGICAL EVALUATION 
The synthesized compounds will be screened for their anti-tubercular activity by in-vitro 
methods. 
 
TOXICOLOGICAL PREDICTION 
Toxicological prediction will be carried out for synthesized compounds by in-silico 
property explorer like OSIRIS. 
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MATERIALS AND METHODS 
 
DRUG DESIGN 
 
Rational drug design (RDD) is the inventive process of finding new medications based 
on the knowledge of the biological target. The drug is an organic small molecule which 
activates or inhibits the function of bio-molecule such as protein, which in turn results 
in a therapeutic benefit to the patient. In the most basic sense, drug design involves 
design of small molecules that are complementary in shape and charge to bimolecular 
target to which they interact and therefore will bind to it. Drug design frequently but not 
necessarily relies in computer modelling techniques. 
 
DOCKING STUDIES (GLIDE) 
DOCKING AND SCORING METHODS: 
           Docking procedure aims to identify the correct binding poses within the binding 
site of the protein while the scoring function aims to predict binding affinity of ligand 
for the protein binding region. The scoring function serves three purposes. 
1. For ranking the conformations generated by the docking, search for one ligand 
interacting with a given protein, this aspect is essential to detect the best binding site 
mode. 
2. For ranking different ligands with respect to binding to one protein i.e. prioritizing 
ligands according to their affinity, this aspect is essential in virtual screening. 
3. For ranking one or different ligands with respect to their binding affinity to different 
proteins their aspect is essential for the consideration of specificity and selectivity. 
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STEPS IN DOCKING: PROTEIN PREPARATION 
A typical PDB file downloaded from protein data bank consists of heavy metals, can 
contain waters, cofactors, metal ions and can be di-meric or multi-meric. The structure 
generally has no information on bond orders, topologies, or formal atomic charges. The 
Terminal groups can also be misaligned because the X-ray structure analysis cannot 
easily distinguish between O and NH2 ion. The ionization and tautomeric states are 
usually unassigned. Generally Glide calculations use an all atom force-field for accurate 
energy evaluation and thus, Glide requires bond orders and ionization states which to be 
properly assigned and should performs better when side chains are reoriented, when 
necessary and steric clashes are relieved. 
The steps for the protein preparation carried out are as follows: 
1. The ligand/protein co-crystallized structure of cmaA1 target (1L1E) in the form of PDB 
was imported into maestro 9.1. The preparation component of a protein preparation 
facility requires an identified ligand which to be verified. 
2. The protein-ligand complex is then identified for its form as dimer or other multimer, 
containing duplicate binding sites, and other duplicate chains that are redundant. Then 
remove the redundant binding sites and the associated chains by picking and deleting 
molecules or chains. 
3. The waters to be identified that bridge between the ligand and protein are retained and 
all the other waters (except those coordinated to metals) are deleted and if waters are 
added then hydrogen can be automatically added and then the orientations of water 
molecules are checked once again. 
4. The protein, metal ions and cofactors are then adjusted. The structures that are missing 
residues near the active sites should be repaired. The covalent bonds from the metal ions 
to the protein should be changed to zero-order bonds. The formal charges on the metal 
and the ligating groups should be adjusted to their appropriate values.  
5. The ligand bond orders and the formal charges are adjusted. In Glide models such 
interactions are associated with vanderwaals and electrostatic interactions. 
6. The restrained minimization of protein structure reorients the side chain containing 
hydroxyl groups and alleviates the potential steric clashes. The minimization is 
restrained to the input protein coordinates by a user-selected RMSD tolerance. 
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LIGAND PREPARATION 
The ligand preparation is designed to prepare a high quality 3 D structures for a large 
numbers of drugs like molecules. The structures which to be docked must have actual 
ligand structures and should meet the following conditions: 
1. The structures must be in three dimensional. 
2. The structures must have realistic bond lengths and bond angles. 
3. Each structure must consist of a single molecule that has no covalent bonds to the 
receptor, with not accompanying fragments such as counter ions and solvent molecules. 
4. All structures must have their hydrogens. 
5. The structures must have an appropriate protonation state for the physiological pH 
values (around 7).     
 The Lig-Prep process consists of a series of steps which perform conversions, eliminate 
unwanted structures, apply corrections to the structures, and optimize the structures. The 
simple use of Lig-Prep produces a single low-energy 3D structure with correct 
chiralities for every successfully processed input structure. The Lig-Prep can also 
produce a large number of structures from each input structure with various ionization 
states, stereo chemistries, and ring conformations, tautomers, and eliminate molecules 
using various criteria including molecular weight, specified numbers and types of 
functional groups which are present. 
 
RECEPTOR GRID GENERATION 
The grid in which the shape and properties of the receptor are represented by a several 
different sets of fields which provide progressively more accurate scoring of the ligand 
poses. Grids must be prepared for each conformation to ensure that possible actives are 
not missed for receptors that adopt more than one conformation on binding. Receptor 
grid defines the receptor structure by excluding any co-crystallised ligand which might 
be present, determine the position and the size of active site as it will be represented by 
receptor grids, set up the glide constraints, and set up the flexible hydroxyl groups. The 
receptor grid generation requires a prepared structure where an all-atom structure with 
appropriate bond orders and formal charges. 
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LIGAND DOCKING 
 
Glide ligand docking job requires a set of previously calculated receptor grids and one 
or more ligand structures. The ligand structures must satisfy the criteria listed above in 
the ligand preparation. The detailed information on setting up grid generation job is 
given above. The preparation of ligands before docking is strongly recommended. The 
Lig-Prep or Macro model in Maestro can be used to prepare ligands. If a correct Lewis 
structure cannot be generated for a ligand, it is skipped by the docking job. 
 
COMPOUND KB01  COMPOUND KB05       COMPOUND KB06 
 
           
N
H
N
O N
O CH3
       
N
H
N
O N
OH
                  
 
G Score: -7.16                                         G Score: -6.11           G Score: -8.24 
INTERACTIONS 
Fig. 04-Interaction between KB01 with 1L1E  
 
 
 
N
H
N
O N
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Fig. 05-Interaction between KB05 with 1L1E 
  
 
 
 
 
Fig. 06-Interaction between KB06 with 1L1E  
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LIPINSKI’S RULE  
Lipinski’s rule of five is a rule of thumb to evaluate drug likeness, or to determine if a 
chemical compound with a certain pharmacological or biological activity has the 
properties that would make it a likely orally active drug in humans. The rule was 
formulated by Christopher A. Lipinski in 1997, based on the observation that most 
medication drugs are relatively small and lipophilic molecules. The rule describes 
molecular properties important for a drug’s pharmacokinetics in the human body, 
including their absorption, distribution, metabolism and excretion (ADME). However, 
the rule does not predict if a compound is pharmacologically active. The rule is 
important for the drug development where a pharmacologically active lead structure is 
optimized step-wise for increased activity and selectivity, as well as drug-like properties 
as described by Lipinski’s rule. The modification of the molecular structure often leads 
to drugs with higher molecular weight, more rings, more rotatable bonds, and a higher 
lipophilicity. 
Lipinski’s rule says that, an orally active drug has no more than one violation of the 
following criteria: 
 Not more than 5 hydrogen bond donors (nitrogen or oxygen atoms with one or more 
hydrogen atoms). 
 Not more than 10 hydrogen bond acceptors (nitrogen or oxygen atoms) 
 A molecular weight under 500 daltons 
 A partition coefficient log P less than 5. 
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COMPOUND KB01 
 
 
COMPOUND KB05 
 
COMPOUND KB06 
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OSIRIS PROPERTY EXPLORER 
OSIRIS property explorer is used in prediction of toxicity of compounds.  Properties with 
high risks of undesired effects like mutagenicity or a poor intestinal absorption are shown 
in red. Whereas a green color indicates drug-conform behavior. It provides the information 
like  
 
 Toxicity risk assessment 
 cLogP Prediction 
 Solubility Prediction 
 Molecular Weights 
 Drug-Likeness Prediction 
 Overall Drug-Likeness Score 
 
                             KB01                                        KB05 
 
 
                                                    KB06 
                                                                                        
 
MATERIALS AND METHODS 
 
 
DEPARTMENT OF PHARMACEUTICAL CHEMISTRY 
 
30 
SYNTHESIS AND CHARACTERISATION 
Reactant Profile 
Structure of Isatin 
N
H
O
O
 
Synonym                    :  1H-indole-2,3-dione 
Molecular Formula   : C8H5NO2                                                                                                                                                 
Formula Weight         :147.1308                                                                                                                  
Melting point              : 201.5 C                                                                                                                      
Solubility                    :  Methanol, Ethanol                                                                                                                                                                                                                            
 
 META PHENYLENE DIAMINE 
 
          Structure                               
                                              
NH2
NH2 
         Synonym                     :  1H-indole-2, 3-dione 
Molecular Formula    : C8H5NO2                                                                                                                                                                            
Formula Weight         :147.1308                                                                                                                   
Melting point              : 65  C                                                                                                                     
Solubility                     : Methanol, Ethanol         
SYNTHETIC SCHEME OF STEP-1          
N
H
O
O
+
NH2
NH2
Acetic acid
Ethanol
Reflex 30 mins N
H
N
O
NH2
     
Isatin                           m-Phenylene Diamine                         Intermediate           
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SYNTHETIC PROCEDURE FOR STEP-1 
Equimolar (0.03398 M) quantity of Isatin(5 g) and the aromatic amine i.e. m-phenylene 
diamine (3.67 g) were taken in a round bottom flask and dissolved in 10-15 ml of warm 
ethanol and added 3-4 drops of dilute acetic acid. It was heated on a steam bath under 
reflux for 30-40 mins. Then the setup was kept aside for 24 hrs. at room temperature. 
The crystalline mass (intermediate) obtained were separated by filtration, vacuum dried 
and recrystallized from ethanol. 
 
SYNTHETIC SCHEME OF STEP-2  
 
N
H
N
O
NH2
+ R-CHO 8 Hrs Reflux
Ethanol
N
H
N
O
N
R
 
Intermediate                            Aromatic Aldehyde                          Product                                                  
from step-1                               (01, 05&06)                                   (KB01, 05&06) 
 
 
 
SYNTHETIC PROCEDURE FOR STEP-2 
Equimolar (0.002M) quantity of intermediate from step-1 and was treated with various 
substituted aromatic aldehyde (1-6) in presence of sodium methoxide. Then the reaction 
mixture was refluxed for 8 hrs. And it was neutralised with dil.Hcl. The resulting 
precipitates were filtered off and recrystallized from ethanol.  
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TABLE-03: SHOWING R-SUBSTITUTION 
COMPOUND  NAME R - denotes 
KB01 
O
 
BENZALDEHYDE 
KB05 
O
O
CH3  
ANISALDEHYDE 
KB06 
O
OH
 
SALICYLALDEHYDE 
     
 
INTERMEDIATE 
 
     Structure  
N
H
N
O
NH2
 
Synonym                     :  (3Z)-3-[(3-aminophenyl) imino]-1, 3-dihydro-2H-indol-2-one       
Molecular Formula    : C14H11N3O                                                                                                                             
Formula Weight         : 237.25664                                                                                                                  
Melting point              : 264  C                                                                                                                     
Solubility                     : Methanol, Ethanol 
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BENZALDEHYDE 
       
  Structure     
                                                                            
O
 
Molecular Formula    :     C7H6O                                                                                                                                                               
Formula Weight         :   106.12194 
 
ANISALDEHYDE 
Structure   
                                    
O
O
CH3  
Synonym                     :  4-Methoxybenzaldehyde 
Molecular Formula    :  C8H8O2 
Formula Weight         : 136.14792 
 
SALICYLALDEHYDE 
Structure 
                    
O
OH
 
Synonym                     :  2-Hydroxybenzaldehyde 
Molecular Formula    :  C7H6O2 
Formula Weight         : 122.12134 
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PRODUCT PROFILE 
 
PHYSICAL PROPERTIES OF COMPOUND KB01 
STRUCTURE 
                                          
N
H
N
O N
 
IUPAC NAME  
                            (3Z)-3-[(3-{[(E)-phenylmethylidene]amino}phenyl)imino]-1,3-
dihydro-2H-indol-2-one 
 
PROPERTIES 
Description          = Brownish red coloured solid mass 
Solubility = Soluble in Methanol, Ethyl acetate, DMSO 
Melting point  = 312°C 
Molecular Formula  = C21H15N3O 
Formula Weight  = 325.3633 
Composition              = C (77.52%) H (4.65%) N (12.91%) O (4.92%) 
Molar Refractivity  = 99.14 ± 0.5 cm
3
 
Molar Volume  = 267.9 ± 7.0 cm
3
 
Parachor             = 710.9 ± 8.0 cm
3
 
Index of Refraction  = 1.661 ± 0.05 
Surface Tension  = 49.5 ± 7.0 dyne/cm 
Density              = 1.21 ± 0.1 g/cm
3
 
Polarizability              = 39.30 ± 0.5 10
-24
cm
3
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PHYSICAL PROPERTIES OF COMPOUND KB05  
 
STRUCTURE 
                                      
N
H
N
O N
O CH3
 
 
IUPAC NAME 
(3Z)-3-[(3-{[(E)-(4-methoxyphenyl)methylidene]amino}phenyl)imino]-1,3-dihydro-
2H-indol-2-one 
 
PROPERTIES 
Description          = Light brown to black colour solid   
Solubility = Soluble in Methanol, Ethanol, Ethyl acetate, DMSO 
Melting point  = 320°C 
Molecular Formula  = C22H17N3O2 
Formula Weight          = 355.38928 
Composition              = C (74.35%) H (4.82%) N (11.82%) O (9.00%) 
Molar Refractivity  = 104.95 ± 0.5 cm
3
 
Molar Volume  = 289.5 ± 7.0 cm
3
 
Parachor               = 761.1 ± 8.0 cm
3
 
Index of Refraction  = 1.644 ± 0.05 
Surface Tension  = 47.7 ± 7.0 dyne/cm 
Density            = 1.22 ± 0.1 g/cm
3
 
Polarizability              = 41.60 ± 0.5 10
-24
cm
3
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PHYSICAL PROPERTIES OF KB06 
 
STRUCTURE 
                                           
N
H
N
O N
OH
 
 
IUPAC NAME 
(3Z)-3-[(3-{[(E)-(2-hydroxyphenyl)methylidene]amino}phenyl)imino]-1,3-dihydro-2H-
indol-2-one 
 
PROPERTIES  
Description          = Brownish yellow coloured crystals 
Solubility = Soluble in Methanol, Ethyl acetate, DMSO 
Melting point  = 290°C 
Molecular Formula  = C21H15N3O2 
Formula Weight  = 341.3627 
Composition      = C (73.89%) H (4.43%) N (12.31%) O (9.37%) 
Molar Refractivity  = 99.99 ± 0.5 cm
3
 
Molar Volume  = 265.1 ± 7.0 cm
3
 
Parachor              = 716.5 ± 8.0 cm
3
 
Index of Refraction  = 1.678 ± 0.05 
Surface Tension   = 53.3 ± 7.0 dyne/cm 
Density              = 1.28 ± 0.1 g/cm
3
 
Polarizability     = 39.64 ± 0.5 10
-24
cm
3
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METHODS OF IDENTIFICATION 
The synthesised compounds were identified by using following methods.  
Melting point:  
The melting points of the compounds were determined by the capillary tube method. 
The synthesised compounds were started losing its crystallinity at a particular 
temperature were found and are present without any correction. 
Thin layer chromatography: 
Pre-coated TLC plates with silicagel GF 250 were used. Samples of reactants and 
products were prepared with its suitable solvent. Among the various mobile phases n-
Hexane: Ethyl acetate (7:3) were selected based on the trial.  
Stationary phase: Pre-coated Silica gel GF250 
Mobile phase: n-Hexane: Ethyl acetate (7:3)  
Detection: UV Chamber  
Location of spots : Spots were visualised  by exposing the plates  in UV chamber. 
 
CHARACTERISATION 
The characterization was carried out using sophisticated methods like Infra-red 
spectroscopy, Nuclear magnetic resonance spectroscopy and Mass spectroscopy. 
INFRA RED ABSORPTION SPECTROSCOPY 
Infra-red absorption spectroscopy (region 2.5µ - 15µ) is a powerful tool for identifying 
pure organic and inorganic compounds because, with the exception of a few homo 
nuclear molecules such as O2, N2, Cl2 all the molecular species absorb infrared 
radiation. With the exception of chiral molecules in the crystalline state, each molecular 
species has a unique infrared absorption spectrum. 
NMR SPECTRA 
Nuclear magnetic resonance involves the interaction between oscillating magnetic field 
of electromagnetic radiation and the magnetic energy of the hydrogen nucleus or some 
other type of nuclei when these are placed in an external static magnetic field.  
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NMR spectroscopy in which radiofrequency waves induces transitions between 
magnetic energy levels of nuclei of a molecule. NMR enables us to study the number of 
equivalent protons and their electronic environment. It reveals the different chemical 
environment in which the proton is present and helps us to ascertain the structure of 
molecules.            
 The number of signals in an NMR spectrum denotes the number of the set of 
equivalent protons in a molecule. The position of the signals in the spectrum helps us to 
know the nature of protons such as aromatic, aliphatic, acetylenic, vinyl, adjacent to 
some electron attracting or electron releasing group etc. The splitting of the signal is 
due to the different environment of the absorbing proton with respect to the adjacent 
protons and not with respect to electrons. 
MASS SPECTROSCOPY 
Mass spectroscopy is an analytical technique used to establish the molecular structure 
and the molecular weight of the analyte under investigation. In this technique, the 
compound under investigation is bombarded with a beam of electrons producing ionic 
fragments of the original species. The relative abundance of the fragment ion formed 
depends on the stability of the ion and of the lost radical. The resulting charged particles 
are then separated according to their masses. Mass spectrum is a record of information 
regarding various masses produced and their relative abundances. 
 
BIOLOGICAL SCREENING FOR ANTI-TB ACTIVITY 
This screening is for the compounds that have the potential to be developed in to new 
drugs against tuberculosis because the compounds inhibit the enzymes required for the 
formation of cell wall of the tuberculosis bacterium. New drugs are needed in current 
date, because the rates of cure with present drugs are very slow, and prevalence of 
mycobacterium tuberculosis resistance to the present drugs is increasing. 
 
 
 
 
 
MATERIALS AND METHODS 
 
 
DEPARTMENT OF PHARMACEUTICAL CHEMISTRY 
 
39 
ASSAY PROCEDURE FOR ESTIMATING ANTI-TB ACTIVITY USING 
Alamar Blue® DYE 
 
1. The anti-mycobacterial activity of compounds was assessed against M. Tuberculosis 
using Alamar Blue® micro plate assay (MABA). 
 
2. This methodology is non-toxic, uses a thermally stable reagent and shows good 
Correlation with proportional and BACTEC radiometric method. 
 
3. Briefly, 200μl of sterile de-ionized water was added to all outer perimeter wells of 
Sterile 96 wells plate to minimized evaporation of medium in the test wells during 
Incubation. 
 
4. The 96 wells plate received 100 μl of the Middle brook 7H9 broth and serial dilution 
of compounds were made directly on plate. 
 
5. The final drug concentrations tested were 100 to 0.2 μg/ml. 
 
6. Plates were covered and sealed with paraffin and incubated at 37ºC for five days. 
 
7. After this time, 25μl of freshly prepared 1:1 mixture of alamar blue® reagent and 
10% tween 80 was added to the plate and incubated for 24 hrs. 
 
8. A blue colour in the well was interpreted as no bacterial growth, and pink colour was 
scored as growth. 
  
9. The MIC was defined as lowest drug concentration which prevented the colour 
change from blue to pink. 
 
RESULTS AND DISCUSSION 
 
 
DEPARTMENT OF PHARMACEUTICAL CHEMISTRY 
 
40 
RESULTS AND DISCUSSION 
Glide Docking  
A promising heterocyclic nucleus isatin (indole2, 3-dione) with proven biological activities 
was used to prepare a data base of compounds which was then docked against mycolic acid 
cyclopropane synthase [cmaA1,  a target (1L1E)] protein for anti-tubercular activity. Glide 
software (Maestro 9.1) was used for this purpose 
Extra precision (XP) scoring function was utilized to rank the order of compounds. The 
different derivatives of isatin were docked to the specific target site. The compounds with best 
G-score were filtered. 
Compounds which had the top G-score had the basic nucleus of isatin linked with m-
phenylene diamine and they were further attached with different substituted aromatic 
aldehydes. The top scored compounds were selected and synthesized. 
LIPINSKI’S RULE 
All the selected compounds of the data base pass the Lipinski’s rule and there is no violation 
in the basic properties. It proves that these molecules have ability to reach the target site for 
the action. So we concluded that the molecules have positive nature on ADME character. 
TOXICITY PREDICTION BY OSIRIS  
OSIRIS property explorer was used for prediction of toxicity of compounds.  Properties of the 
synthesized compounds such as high risks of undesired effects like mutagenicity, poor 
intestinal absorption and drug-like behavior can be predicted by this method. These properties 
are shown different color indication. It provides information like,  
 Toxicity risk assessment 
 cLogP Prediction 
 Solubility Prediction 
 Molecular Weights 
 Drug-Likeness Prediction 
 Overall Drug-Likeness Score 
RESULTS AND DISCUSSION 
 
 
DEPARTMENT OF PHARMACEUTICAL CHEMISTRY 
 
41 
SYNTHESIS AND CHARACTERIZATION 
SYNTHESIS 
 The compounds KB 01, KB05 & KB 06 were prepared from isatin by 2 steps. In the first step 
an intermediate compound was synthesized by condensing the isatin and m-phenylene 
diamine in the presence of few drops of acetic acid.  In the 2
nd 
step, the intermediate was 
further treated with different substituted aromatic aldehydes to give different final (KB 01, 
KB05&KB 06) products. 
CHARACTERIZATION       
The synthesized compounds were recrystallized and identified as pure by TLC method. The 
melting points of the compounds were checked and are presented uncorrected. Further 
characterization was carried out by IR, NMR and Mass Spectroscopy. 
IR SPECTROSOPY 
An IR spectrum of all the synthesized compounds was taken and was used for identification of 
the functional groups. 
The presence of starting material as impurity was ruled out by examining for the absence of 
characteristic stretching for the starting materials. 
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IR SPECTRUM OF KB01 
 
 
 
COMPOUND NAME IR REGION 
KB01 
3062.73 (Ar-CH),  
1481.22 (Ar C=C), 
1704.85 (C=O),  
3355.89 (N-H),  
1103.20 (C-N), 
1620.09 (C=N),  
2929.87 (Al C-H) 
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NMR SPECTRUM OF KB01 
 
 
COMPOUND NAME H
1
 NMR 
KB01 
6.2-7.8δ (11H, m,  Ar C-H)  
7.8-8.2 δ (2H, s, Ar C-H) 
 1.4δ (1H, s, Al C-H)  
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MASS SPECTRUM OF KB01 
 
COMPOUND NAME m/e VALUE 
KB01 
325.46 (M
+
) 
57.16 (B) 
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IR SPECTRUM OF KB05 
 
COMPOUND NAME IR REGION 
KB05 
3070.45 (Ar-CH),  
1465.79 (Ar C=C),  
1712.66 (C=O),  
1103.20 (C-N), 
 3348.16  (N-H), 
1596.94 (C=N),  
2916.16 (Al-CH),  
1257.50 (C-O-C). 
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NMR SPECTRUM OF KB05 
 
COMPOUND NAME H
1
 NMR 
KB05 
1.1-1.4δ (1H, s Al C-H) 
2.5-2.8δ (3H, s, O-CH3) 
6.8-8.5δ (12H, m, Ar C-H) 
10.2-11δ (1H, s, N-H) 
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MASS SPECTRUM OF KB05 
 
COMPOUND NAME m/e VALUE 
KB05 
355.25 (M
+
) 
57.16 (B) 
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IR SPECTRUM OF KB06 
 
COMPOUND NAME IR REGION 
KB06 
3062.73 (Ar-CH),  
1481.22 (Ar C=C),  
1720.38 (C=O),  
1110.92 (C-N),  
1612.37 (C=N),  
2916.16 (Al-CH),  
3695.34 (phenolic OH),  
3271.03 (N-H),  
1143.49 (C-O). 
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NMR SPECTRUM OF KB06 
 
COMPOUND NAME H
1 
NMR 
KB06 
2.2-2.8δ (1H, s, Al C-H) 
6.5-7.9 δ (12H, m, Ar C-H) 
10.2-10.5 δ (1H, s,  Ar O-H) 
12.8-13.2 δ (1H, s, N-H) 
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MASS SPECTRUM OF KB06 
 
COMPOUND NAME m/e VALUE 
KB06 
341.38 (M
+
) 
57.16 (B) 
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BIOLOGICAL EVALUATION 
The anti-tubercular activities of the synthesized compounds were determined by MABA 
method. Mycobacterium tuberculosis (H37 RV Strain) was used. The pathogen tested was 
susceptible to all the three compounds at 100µg/ml and 50µg/ml. The data pertaining to those 
observations are presented in the table and the growth of organism is shown in figure. 
Inhibition was compared using standard streptomycin [6.25µg/ml] and pyrazinamide 
[3.12µg/ml] & ciprofloxacin [3.12µg/ml]. 
TABLE-04: Results for Anti tubercular activity 
S.No. 
Compound 
code 
100 
µg/ml 
50 
µg/ml 
25 
µg/ml 
12.5 
µg/ml 
6.25 
µg/ml 
3.12 
µg/ml 
1.6 
µg/ml 
0.8 
µg/ml 
1 KB01 S S R R R R R R 
2 KB05 S S R R R R R R 
3 KB06 S S R R R R R R 
 
 NOTE:  
S - Sensitive  
R - Resistant  
Strain used: M.tuberculosis (H37 RV strain) 
STANDARD VALUES 
Pyrazinamide- 3.125μg/ml  
Streptomycin- 6.25μg/ml  
Ciprofloxacin-3.125μg/ml 
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Figure-07: Photograph of Alamar Blue Assay 
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SUMMARY AND CONCLUSION 
 
DRUG DESIGN AND DOCKING 
All the designed molecules were docked to the specific target i.e., cmaA1 target (1L1E) 
mycolic acid cyclopropane synthase using drug design software (GLIDE Maestro 9.1).  
Those molecules with the top G-Score molecules which possessed synthetic feasibility 
were selected and others were ruled out. 
SYNTHESIS AND CHARACTERIZATION 
The chosen compounds were synthesized by the conventional method and checked for 
purity initially by TLC and melting point methods. The structure of the synthesized 
compounds was assigned on the basis of spectral studies of IR, H
1
NMR and Mass 
spectroscopy method. All the synthesized compounds comply with the spectral 
requirements. 
BIOLOGICAL SCREENING 
Invitro Anti-tubercular activity: 
The synthesized compound [KB01, KB05 & KB06] showed the anti-tubercular activity. 
The pathogen tested was susceptible to all the synthesized compounds at 100µg/ml and 
50µg/ml concentration. This proved that the docking method with GLIDE [Maestro 9.1] 
is ideal and fruitful for predicting biological activity.  
 Toxicological prediction: 
Toxicity prediction was done by the in silico approaches using Osiris property explorer 
software. It shows for all the synthesized compounds are found to be no risk of undesired 
effects like tumorigenic, reproductive effective. But it shows some extent of undesired 
effects like mutagenicity and irritant quality.  
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CONCLUSION 
This dissertation concludes that our synthesized compounds are effective in inhibiting the 
mycolic acid cyclopropane synthase (cmaA1) which is important for the growth of         
mycobacterium tuberculosis. 
The structural improvement in the structure of the synthesized compounds can give new 
outlook to the development of promising molecules against the pathogen mycobacterium 
tuberculosis. 
Acute and chronic toxicity studies can be carried out. These compounds can be evaluated 
for synergistic properties when combined with other enzyme inhibitors which act along 
the sequence of all wall synthesis. 
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